TGTX Tg Therapeutics Inc

Price (delayed)

$34.52

Market cap

$4.93B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.73

Enterprise value

$4.56B

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active ...

Highlights
Tg Therapeutics's gross profit has surged by 177% QoQ
The revenue has soared by 166% QoQ
The equity has surged by 97% year-on-year but it has declined by 14% since the previous quarter
The quick ratio has increased by 24% YoY but it has decreased by 11% QoQ
The company's net income has shrunk by 68% YoY and by 8% QoQ
Tg Therapeutics's EPS has decreased by 33% YoY and by 4.6% QoQ

Key stats

What are the main financial stats of TGTX
Market
Shares outstanding
142.83M
Market cap
$4.93B
Enterprise value
$4.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.75
Price to sales (P/S)
1,888.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,889.37
Earnings
Revenue
$2.41M
EBIT
-$338.08M
EBITDA
-$337.86M
Free cash flow
-$250.57M
Per share
EPS
-$2.73
Free cash flow per share
-$1.9
Book value per share
$2.71
Revenue per share
$0.02
TBVPS
$3.64
Balance sheet
Total assets
$481.4M
Total liabilities
$98.27M
Debt
$33.34M
Equity
$383.13M
Working capital
$367.52M
Liquidity
Debt to equity
0.09
Current ratio
5.2
Quick ratio
5.09
Net debt/EBITDA
1.09
Margins
EBITDA margin
-13,996%
Gross margin
88.1%
Net margin
-14,271.2%
Operating margin
-14,051.2%
Efficiency
Return on assets
-71.4%
Return on equity
-90.8%
Return on invested capital
-2,766.8%
Return on capital employed
-85.8%
Return on sales
-14,005.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TGTX stock price

How has the Tg Therapeutics stock price performed over time
Intraday
7.34%
1 week
12.44%
1 month
27.52%
1 year
39.64%
YTD
-33.64%
QTD
-11.01%

Financial performance

How have Tg Therapeutics's revenue and profit performed over time
Revenue
$2.41M
Gross profit
$2.13M
Operating income
-$339.2M
Net income
-$344.51M
Gross margin
88.1%
Net margin
-14,271.2%
Tg Therapeutics's gross profit has surged by 177% QoQ
The revenue has soared by 166% QoQ
TGTX's net margin has soared by 89% YoY and by 59% QoQ
Tg Therapeutics's operating margin has surged by 89% YoY and by 59% QoQ

Growth

What is Tg Therapeutics's growth rate over time

Valuation

What is Tg Therapeutics stock price valuation
P/E
N/A
P/B
12.75
P/S
1,888.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,889.37
Tg Therapeutics's EPS has decreased by 33% YoY and by 4.6% QoQ
The equity has surged by 97% year-on-year but it has declined by 14% since the previous quarter
The P/B is 21% below the 5-year quarterly average of 16.1 and 18% below the last 4 quarters average of 15.6
The revenue has soared by 166% QoQ
The P/S is 89% below the last 4 quarters average of 17396.1 and 75% below the 5-year quarterly average of 7431.4

Efficiency

How efficient is Tg Therapeutics business performance
Tg Therapeutics's return on sales has surged by 89% YoY and by 59% QoQ
The company's return on equity has surged by 77% YoY and by 5% QoQ
The ROA has grown by 43% YoY and by 2.5% from the previous quarter
TGTX's ROIC is up by 35% QoQ but it is down by 24% YoY

Dividends

What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TGTX.

Financial health

How did Tg Therapeutics financials performed over time
The total assets has soared by 63% YoY but it fell by 12% QoQ
TGTX's current ratio is up by 25% year-on-year but it is down by 10% since the previous quarter
TGTX's debt is 91% lower than its equity
The equity has surged by 97% year-on-year but it has declined by 14% since the previous quarter
The debt to equity has plunged by 55% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.